Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, rest of Europe, North America, Latin America, China, India, Japan, rest of Asia, and internationally. More Details
Excellent balance sheet second-rate dividend payer.
Share Price & News
How has Koninklijke DSM's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DSM is less volatile than 75% of Dutch stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: DSM's weekly volatility (2%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: DSM underperformed the Dutch Chemicals industry which returned 37% over the past year.
Return vs Market: DSM underperformed the Dutch Market which returned 31.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Koninklijke DSM's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShareholders Of Koninklijke DSM (AMS:DSM) Must Be Happy With Their 224% Total Return
1 month ago | Simply Wall StKoninklijke DSM N.V.'s (AMS:DSM) Intrinsic Value Is Potentially 17% Below Its Share Price
1 month ago | Simply Wall StOnly Four Days Left To Cash In On Koninklijke DSM's (AMS:DSM) Dividend
Is Koninklijke DSM undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DSM (€156.75) is trading above our estimate of fair value (€150.03)
Significantly Below Fair Value: DSM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DSM is poor value based on its PE Ratio (60x) compared to the Dutch Chemicals industry average (31.8x).
PE vs Market: DSM is poor value based on its PE Ratio (60x) compared to the Dutch market (28.4x).
Price to Earnings Growth Ratio
PEG Ratio: DSM is poor value based on its PEG Ratio (3.6x)
Price to Book Ratio
PB vs Industry: DSM is overvalued based on its PB Ratio (3.6x) compared to the NL Chemicals industry average (3.5x).
How is Koninklijke DSM forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DSM's forecast earnings growth (16.6% per year) is above the savings rate (0.1%).
Earnings vs Market: DSM's earnings (16.6% per year) are forecast to grow faster than the Dutch market (15.3% per year).
High Growth Earnings: DSM's earnings are forecast to grow, but not significantly.
Revenue vs Market: DSM's revenue (5.7% per year) is forecast to grow slower than the Dutch market (6.4% per year).
High Growth Revenue: DSM's revenue (5.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DSM's Return on Equity is forecast to be low in 3 years time (11.9%).
How has Koninklijke DSM performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DSM has high quality earnings.
Growing Profit Margin: DSM's current net profit margins (5.5%) are lower than last year (8.4%).
Past Earnings Growth Analysis
Earnings Trend: DSM's earnings have grown by 3.7% per year over the past 5 years.
Accelerating Growth: DSM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DSM had negative earnings growth (-33.7%) over the past year, making it difficult to compare to the Chemicals industry average (20.7%).
Return on Equity
High ROE: DSM's Return on Equity (6.1%) is considered low.
How is Koninklijke DSM's financial position?
Financial Position Analysis
Short Term Liabilities: DSM's short term assets (€5.4B) exceed its short term liabilities (€2.3B).
Long Term Liabilities: DSM's short term assets (€5.4B) exceed its long term liabilities (€4.6B).
Debt to Equity History and Analysis
Debt Level: DSM's debt to equity ratio (45.1%) is considered high.
Reducing Debt: DSM's debt to equity ratio has reduced from 53.5% to 45.1% over the past 5 years.
Debt Coverage: DSM's debt is well covered by operating cash flow (44.3%).
Interest Coverage: DSM's interest payments on its debt are well covered by EBIT (9.2x coverage).
What is Koninklijke DSM current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DSM's dividend (1.53%) isn’t notable compared to the bottom 25% of dividend payers in the Dutch market (1.58%).
High Dividend: DSM's dividend (1.53%) is low compared to the top 25% of dividend payers in the Dutch market (4.57%).
Stability and Growth of Payments
Stable Dividend: DSM's dividends per share have been stable in the past 10 years.
Growing Dividend: DSM's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (91.9%), DSM's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: DSM's dividends in 3 years are forecast to be well covered by earnings (47.4% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dimitri de Vreeze (54 yo)
Mr. Dimitri de Vreeze serves as Chief Operating Officer of DSM Nutritional Products AG and has been its Chief Executive Officer and President since April 1, 2021. He serves as President of DSM Resins at DS...
CEO Compensation Analysis
Compensation vs Market: Dimitri's total compensation ($USD3.15M) is about average for companies of similar size in the Dutch market ($USD3.15M).
Compensation vs Earnings: Dimitri's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: DSM's management team is considered experienced (4.2 years average tenure).
Experienced Board: DSM's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DSM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Koninklijke DSM N.V.'s company bio, employee growth, exchange listings and data sources
- Name: Koninklijke DSM N.V.
- Ticker: DSM
- Exchange: ENXTAM
- Founded: 1902
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: €26.770b
- Shares outstanding: 170.78m
- Website: https://www.dsm.com
Number of Employees
- Koninklijke DSM N.V.
- Het Overloon 1
- 6411 TE
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, rest of Europe, North America, Latin America, China, India, Japan, rest of...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/23 23:31|
|End of Day Share Price||2021/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.